|
1.
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Liedtke C, Mazouni C, Hess KR, et al:
Response to neoadjuvant therapy and long-term survival in patients
with triple-negative breast cancer. J Clin Oncol. 26:1275–1281.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Thike AA, Cheok PY, Jara-Lazaro AR, et al:
Triple-negative breast cancer: clinicopathological characteristics
and relationship with basal-like breast cancer. Mod Pathol.
23:123–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Dent R, Trudeau M, Pritchard KI, et al:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Isakoff SJ: Triple-negative breast cancer:
role of specific chemotherapy agents. Cancer J. 16:53–61. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Marquette C and Nabell L:
Chemotherapy-resistant metastatic breast cancer. Curr Treat Options
Oncol. 13:263–275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Chen ZS and Tiwari AK: Multidrug
resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic
diseases. FEBS J. 278:3226–3245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Abraham J, Edgerly M, Wilson R, et al: A
phase I study of the P-glycoprotein antagonist tariquidar in
combination with vinorelbine. Clin Cancer Res. 15:3574–3582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ruff P, Vorobiof DA, Jordaan JP, et al: A
randomized, placebo-controlled, double-blind phase 2 study of
docetaxel compared to docetaxel plus zosuquidar (LY335979) in women
with metastatic or locally recurrent breast cancer who have
received one prior chemotherapy regimen. Cancer Chemother
Pharmacol. 64:763–768. 2009. View Article : Google Scholar
|
|
11.
|
Zheng G, Peng F, Ding R, et al:
Identification of proteins responsible for the multiple drug
resistance in 5-fluorouracil-induced breast cancer cell using
proteomics analysis. J Cancer Res Clin Oncol. 136:1477–1488. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Nakamura A, Nakajima G, Okuyama R, et al:
Enhancement of 5-fluorouracil-induced cytotoxicity by leucovorin in
5-fluorouracil-resistant gastric cancer cells with upregulated
expression of thymidylate synthase. Gastric Cancer. Mar
15–2013.(Epub ahead of print).
|
|
13.
|
Kodera Y, Ito S, Fujiwara M, et al: Gene
expression of 5-fluorouracil metabolic enzymes in primary gastric
cancer: correlation with drug sensitivity against 5-fluorouracil.
Cancer Lett. 252:307–313. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ichikawa W, Takahashi T, Suto K, et al:
Thymidylate synthase predictive power is overcome by irinotecan
combination therapy with S-1 for gastric cancer. Br J Cancer.
91:1245–1250. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Zhang X, Yashiro M, Qiu H, et al:
Establishment and characterization of multidrug-resistant gastric
cancer cell lines. Anticancer Res. 30:915–921. 2010.PubMed/NCBI
|
|
17.
|
Uchibori K, Kasamatsu A, Sunaga M, et al:
Establishment and characterization of two 5-fluorouracil-resistant
hepatocellular carcinoma cell lines. Int J Oncol. 40:1005–1010.
2012.PubMed/NCBI
|
|
18.
|
Yanagihara K, Takigahira M, Tanaka H, et
al: Establishment and molecular profiling of a novel human
pancreatic cancer panel for 5-FU. Cancer Sci. 99:1859–1864. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Kakehashi A, Ishii N, Shibata T, et al:
Mitochondrial prohibitins and septin 9 are implicated in the onset
of rat hepatocarcinogenesis. Toxicol Sci. 119:61–72. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Park JS, Young Yoon S, Kim JM, et al:
Identification of novel genes associated with the response to 5-FU
treatment in gastric cancer cell lines using a cDNA microarray.
Cancer Lett. 214:19–33. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Shieh SY, Ikeda M, Taya Y, et al: DNA
damage-induced phosphorylation of p53 alleviates inhibition by
MDM2. Cell. 91:325–334. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Tibbetts RS, Brumbaugh KM, Williams JM, et
al: A role for ATR in the DNA damage-induced phosphorylation of
p53. Genes Dev. 13:152–157. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Shin JY, Kim JO, Lee SK, et al: LY294002
may overcome 5-FU resistance via down-regulation of activated p-AKT
in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer.
10:4252010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Yanamoto S, Iwamoto T, Kawasaki G, et al:
Silencing of the p53R2 gene by RNA interference inhibits growth and
enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer
Lett. 223:67–76. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Chu E, Drake JC, Koeller DM, et al:
Induction of thymidylate synthase associated with multidrug
resistance in human breast and colon cancer cell lines. Mol
Pharmacol. 39:136–143. 1991.PubMed/NCBI
|
|
27.
|
Peters GJ, Backus HH, Freemantle S, et al:
Induction of thymidylate synthase as a 5-fluorouracil resistance
mechanism. Biochim Biophys Acta. 1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Chen J, Shen BY, Deng XX, et al:
SKP1-CULLIN1-F-box (SCF)-mediated DRG2 degradation facilitated
chemotherapeutic drugs induced apoptosis in hepatocellular
carcinoma cells. Biochem Biophys Res Commun. 420:651–655. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Nakayama KI and Nakayama K: Ubiquitin
ligases: cell-cycle control and cancer. Nat Rev Cancer. 6:369–381.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Chan CH, Li CF, Yang WL, et al: The
Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis,
herceptin sensitivity, and tumorigenesis. Cell. 149:1098–1111.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Zhu D, Cardenas ME and Heitman J:
Calcineurin mutants render T lymphocytes resistant to cyclosporin
A. Mol Pharmacol. 50:506–511. 1996.PubMed/NCBI
|
|
32.
|
Colgan J, Asmal M, Yu B, et al:
Cyclophilin A-deficient mice are resistant to immunosuppression by
cyclosporine. J Immunol. 174:6030–6038. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Wong CS, Wong VW, Chan CM, et al:
Identification of 5-fluorouracil response proteins in colorectal
carcinoma cell line SW480 by two-dimensional electrophoresis and
MALDI-TOF mass spectrometry. Oncol Rep. 20:89–98. 2008.PubMed/NCBI
|
|
34.
|
Kuramitsu Y, Taba K, Ryozawa S, et al:
Identification of up- and down-regulated proteins in
gemcitabine-resistant pancreatic cancer cells using two-dimensional
gel electrophoresis and mass spectrometry. Anticancer Res.
30:3367–3372. 2010.PubMed/NCBI
|
